← Back to Search

Curcumin Therapy for COPD

N/A
Waitlist Available
Led By Oleg Sostin, MD
Research Sponsored by Danbury Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months

Summary

This trial tests if curcumin, a substance from turmeric, can help people with COPD by reducing lung inflammation. The study targets COPD patients who still suffer from severe symptoms and frequent hospital visits despite current treatments.

Who is the study for?
This trial is for individuals with COPD who have smoked at least 10 pack-years, have specific lung function test results, and haven't had a flare-up in the last month. They must not use turmeric recently or be on certain medications, pregnant, lactating, or unable to do a walking test due to non-COPD issues.
What is being tested?
The study tests if curcumin therapy improves COPD management over 90 days compared to placebo. All participants will continue their usual care. The effects of curcumin are measured against those receiving an inactive substance in this double-blind setup where neither doctors nor patients know who's getting what.
What are the potential side effects?
Curcumin is generally considered safe but may cause digestive upset like nausea or diarrhea in some people. Since it's being tested alongside standard treatments for COPD, other side effects could include typical reactions to those existing medications.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
St. George's Respiratory Questionnaire (SGRQ-C) score
Secondary study objectives
Performance on the 6-minute walk test (6MWT)
Relative risk of hospital admission for acute COPD exacerbation.
Chronic Obstructive Airway Disease
+1 more

Trial Design

2Treatment groups
Active Control
Group I: Active Comparator: Placebo with Standard COPD careActive Control2 Interventions
Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.
Group II: Active Comparator: Curcumin therapy added to standard COPD careActive Control2 Interventions
Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.

Find a Location

Who is running the clinical trial?

Danbury HospitalLead Sponsor
10 Previous Clinical Trials
1,239 Total Patients Enrolled
Oleg Sostin, MDPrincipal InvestigatorDanbury Hospital, Nuvance Health

Media Library

Active Comparator: Curcumin therapy added to standard COPD care Clinical Trial Eligibility Overview. Trial Name: NCT04687449 — N/A
Chronic Obstructive Pulmonary Disease Research Study Groups: Active Comparator: Placebo with Standard COPD care, Active Comparator: Curcumin therapy added to standard COPD care
Chronic Obstructive Pulmonary Disease Clinical Trial 2023: Active Comparator: Curcumin therapy added to standard COPD care Highlights & Side Effects. Trial Name: NCT04687449 — N/A
Active Comparator: Curcumin therapy added to standard COPD care 2023 Treatment Timeline for Medical Study. Trial Name: NCT04687449 — N/A
~31 spots leftby Dec 2025